[go: up one dir, main page]

UA109242U - STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR - Google Patents

STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR

Info

Publication number
UA109242U
UA109242U UAU201510846U UAU201510846U UA109242U UA 109242 U UA109242 U UA 109242U UA U201510846 U UAU201510846 U UA U201510846U UA U201510846 U UAU201510846 U UA U201510846U UA 109242 U UA109242 U UA 109242U
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
composition containing
stable pharmaceutical
proteasom
inhibitor
Prior art date
Application number
UAU201510846U
Other languages
Ukrainian (uk)
Original Assignee
Федорович Павло Іванович
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федорович Павло Іванович filed Critical Федорович Павло Іванович
Priority to UAU201510846U priority Critical patent/UA109242U/en
Publication of UA109242U publication Critical patent/UA109242U/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Стабільна дозована фармацевтична композиція для лікування множинної мієломи у складі комбінованої терапії, що містить інгібітор протеасом і фармацевтично прийнятні ексципієнти, має форму ліофілізованого порошку для внутрішньовенного введення, причому як інгібітор протеасом містить бортезоміб або його фармацевтично прийнятні гідрат, сольват, безводну форму, складний ефір, тримерну форму.Stable dosage pharmaceutical composition for the treatment of multiple myeloma in combination therapy containing proteasome inhibitor and pharmaceutically acceptable excipients, having the form of a lyophilized powder for intravenous administration, and as a proteasome inhibitor contains bortezomib or its pharmaceutically acceptable hydrate, solvate, solvate three-dimensional shape.

UAU201510846U 2015-11-06 2015-11-06 STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR UA109242U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201510846U UA109242U (en) 2015-11-06 2015-11-06 STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201510846U UA109242U (en) 2015-11-06 2015-11-06 STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR

Publications (1)

Publication Number Publication Date
UA109242U true UA109242U (en) 2016-08-25

Family

ID=56707597

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201510846U UA109242U (en) 2015-11-06 2015-11-06 STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR

Country Status (1)

Country Link
UA (1) UA109242U (en)

Similar Documents

Publication Publication Date Title
MX2022001755A (en) Cyclic di-nucleotide compounds and methods of use.
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
EA201792592A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2016003522A (en) Quinazoline derivatives and their use as dna methyltransferase inhibitors.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
EA201501164A1 (en) SOLID PHARMACEUTICAL MEDICINE FORM
MX2022013450A (en) Pharmaceutical formulations.
MX2019005309A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use.
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
TR201310724A2 (en) Pharmaceutical formulati̇ons of linagliptin
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
MX2017002627A (en) Derivatives of macrocyclic n-aryl-2-amino-4-aryl-pyrimidine polyethers as inhibitors of ftl3 and jak.
MX2017002544A (en) Isoquinolinone derivatives useful in the treatment of cancer.
MX2018015759A (en) Vortioxetine dosing regimes for fast onset of antidepressant effect.
UA109242U (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR
MX2016017315A (en) Pharmaceutical dosage forms.
MX2018013428A (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine.
MX2017002747A (en) Derivatives of macrocyclic n-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of ftl3 and jak.